Raiffeisen Bank International AG Grows Position in Alnylam Pharmaceuticals, Inc. $ALNY

Raiffeisen Bank International AG lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 29.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,510 shares of the biopharmaceutical company’s stock after buying an additional 3,097 shares during the period. Raiffeisen Bank International AG’s holdings in Alnylam Pharmaceuticals were worth $3,965,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. iA Global Asset Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 979.5% in the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after buying an additional 16,133 shares during the period. SCS Capital Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $34,784,000. Hsbc Holdings PLC raised its position in shares of Alnylam Pharmaceuticals by 22.6% during the 4th quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock valued at $35,675,000 after buying an additional 16,503 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Alnylam Pharmaceuticals in the second quarter valued at approximately $50,773,000. Finally, Keystone Investors PTE Ltd. purchased a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $3,531,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ALNY shares. JPMorgan Chase & Co. cut their target price on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Truist Financial decreased their price target on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. TD Cowen reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Monday. Raymond James Financial raised Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price objective for the company in a research report on Monday, August 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $455.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $386.14.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $266.11 on Friday. The company has a market cap of $35.61 billion, a P/E ratio of 49.46 and a beta of 0.31. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The stock has a 50-day moving average of $259.25 and a two-hundred day moving average of $291.61. Alnylam Pharmaceuticals, Inc. has a 1-year low of $197.81 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.63 by $0.21. The business had revenue of $1.29 billion for the quarter, compared to analysts’ expectations of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The business’s quarterly revenue was up 66.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.51) earnings per share. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.